Novo Nordisk's '2-in-3 Indians Have Fatty Liver' Claim Overstates Published Epidemiological Evidence

Mainstream NAFLD/MASLD prevalence estimates for India's general population run 9–32%; the company's investor-facing figure appears inflated by commercial framing and unverified sourcing.

bt-corporate · 7/17/2026, 10:03:25 AM · Ask about this →